science

Teprotumumab

Teprotumumab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Teprotumumab rather than just read about it. In short: Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (Graves' eye disease), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumor treatment but was later developed by River Vision Development Corporation and Horizon Therapeutics to…

Key takeaways

Teprotumumab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Teprotumumab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Teprotumumab from memory before moving on to harder problems.

Reference excerpt

Teprotumumab, sold under the brand name Tepezza, is a medication used to treat thyroid eye disease (Graves' eye disease), a rare condition where the muscles and fatty tissues behind the eye become inflamed, causing the eyes to bulge outwards. It is a human monoclonal antibody developed by Genmab and Roche for tumor treatment but was later developed by River Vision Development Corporation and Horizon Therapeutics to be used for ophthalmic uses. It binds to IGF-1R. The most common side effects are muscle spasm, nausea, hair loss, diarrhea, fatigue, high blood sugar, hearing loss, dry skin, altered sense of taste, and headache. Teprotumumab should not be used if pregnant. Teprotumumab was approved for medical use in the United States in January 2020. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

Medical use Teprotumumab is indicated for the treatment of thyroid eye disease.

History In a multi-center, randomized trial in participants with active Graves' ophthalmopathy, teprotumumab was more effective than placebo. In February 2019, Horizon announced results from a Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more participants treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9% of teprotumumab participants compared to 9.5% of placebo participants achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase II study of teprotumumab in TED. In July 2019, Horizon submitted a biologics license application to the US Food and Drug Administration (FDA) for teprotumumab for the treatment of active thyroid eye disease. Teprotumumab was first investigated for the treatment of solid and hematologic tumors, including breast cancer, Hodgkin's and non-Hodgkin's lymphoma, non-small cell lung cancer, and sarcoma. Teprotumumab-trbw was approved based on the results of two clinical trials (Trial 1/ NCT01868997 and Trial 2/ NCT03298867) of 170 subjects with active TED who were randomized to either receive teprotumumab-trbw or a placebo. Of the subjects who were administered Tepezza, 71% in study 1 and 83% in study 2 demonstrated a greater than 2 mm reduction in proptosis (eye protrusion) as compared to 20% and 10% of subjects who received placebo, respectively. The trials were conducted at 28 sites in Europe and United States. Teprotumumab-trbw was approved for use in the United States in January 2020, for the treatment of adults with thyroid eye disease. The FDA granted the application for teprotumumab-trbw fast-track, breakthrough therapy, priority review, and orphan drug designations. The FDA granted the approval of Tepezza to Horizon Therapeutics Ireland DAC.

Society and culture

Legal status In April 2025, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Tepezza, intended for the treatment of adults with moderate to severe thyroid eye disease. The applicant for this medicinal product is Amgen Europe B.V. Teprotumumab was authorized for medical use in the European Union in June 2025. The CHMP's opinion is based on data from three randomized, placebo-controlled trials in a total of 225 participants with active thyroid eye disease, and one trial in 62 participants with chronic thyroid eye disease. After 24 weeks, participants treated with teprotumumab experienced a significant reduction (-2 to -2.3 mm) in protrusion of the eyeball from the eye socket (proptosis) and in the clinical activity score, a standard tool to evaluate inflammatory signs and symptoms of thyroid eye disease, compared to participants treated with placebo. The reduction in proptosis was smaller (-1.5mm) in participants with chronic thyroid eye disease.

References

Worked examples

Example 1 — a first encounter with Teprotumumab

Start with the simplest possible case. Write down what Teprotumumab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Teprotumumab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Teprotumumab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Teprotumumab

In research: Teprotumumab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Teprotumumab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Teprotumumab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Drugs developed by Hoffmann-La Roche, Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Teprotumumab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Teprotumumab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Teprotumumab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Teprotumumab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Teprotumumab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Teprotumumab in simple terms?

Why does Teprotumumab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Teprotumumab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Teprotumumab.